BTN2A1

BTN2A1 is a cell-surface butyrophilin that serves as a direct, germline-encoded ligand for the Vγ9 chain of the Vγ9Vδ2 T cell receptor, functioning as the obligatory partner of BTN3A in phosphoantigen (pAg)-driven γδ T cell cytotoxicity against tumor cells (PMID:34260935). Co-expression of BTN2A1 with BTN3A1 is sufficient to trigger Vγ9Vδ2 TCR activation; BTN2A1 interacts with all three BTN3A isoforms, and this interaction is rate-limiting for BTN2A1 export to the plasma membrane (PMID:34260935). Phosphoantigen sensing operates through the intracellular B30.2 domains: HMBPP binds the B30.2 domain of BTN3A1, not BTN2A1, and bridges the two cytoplasmic domains, with BTN2A1 B30.2 homodimerization required for engagement of HMBPP-bound BTN3A1 [PMID:37171180, PMID:bio_10.1101_2024.10.02.616253]. At the cell surface the BTN2A1 and BTN3A IgV domains assemble in cis, but TCR and BTN3A1-IgV binding to BTN2A1-IgV are mutually exclusive, and pAg-induced conformational changes in the BTN3A1 B30.2 domain drive a rearrangement in which the BTN3A2–BTN2A1 ectodomain contact dissociates so that BTN2A1 engages the lateral surface of Vγ9 in a composite-ligand, 'pliers-like gripping' mechanism [PMID:36995939, PMID:40079188, PMID:bio_10.1101_2024.10.02.616253]. Tumor-specific upregulation of surface BTN2A1 follows oncogenic transformation and can be induced pharmacologically through AMPK signaling, and agonist anti-BTN2A1 antibodies enhance γδ T cell killing and trigger caspase 3/7-mediated tumor pyroptosis (PMID:39302336, PMID:42248853). Independently of γδ T cell recognition, BTN2A1 is a Ca2+-dependent ligand for DC-SIGN on immature dendritic cells via high-mannose glycans enriched on tumor cells, and antibody engagement of BTN2A1 on M2-like macrophages drives SYK- and ERK-dependent reprogramming toward an M1-like phenotype (PMID:17785817, PMID:39325623).

1. 2007 High

   Before any γδ T cell role was known, BTN2A1 was first identified as a cell-surface glycoprotein ligand, establishing it as a glycan-dependent immune recognition molecule.

   Evidence Ig-fusion protein and DC-SIGN-transfectant binding assays with glycosylation analysis on dendritic cells

   PMID:17785817

   Open questions at the time

   • Did not connect BTN2A1 to T cell biology or BTN3A
   • Functional consequence of DC-SIGN engagement for DC differentiation not resolved
2. 2021 High

   Resolved the central question of what licenses BTN3A-mediated γδ T cell activation by identifying BTN2A1 as the required partner and a direct Vγ9Vδ2 TCR ligand.

   Evidence Cytotoxicity assays, co-expression reconstitution, antibody inhibition, and B30.2 domain mutagenesis in cancer cells

   PMID:34260935

   Open questions at the time

   • Molecular geometry of the BTN2A1/BTN3A/TCR assembly unresolved
   • How pAg enhances the interaction not mechanistically defined
3. 2022 Medium

   Established that BTN2A1/BTN3A1 provides 'signal 1' but requires costimulation, refining the requirements for productive γδ T cell engagement and enabling therapeutic engager design.

   Evidence Tumor cell-free activation assays with a BTN2A1/BTN3A1 heterodimeric fusion protein and CD28/NKG2D costimulation dissection

   PMID:36096643

   Open questions at the time

   • Stoichiometry of the engineered heterodimer vs native complex unclear
   • Costimulatory ligand requirements in primary tumors not mapped
4. 2023 High

   Defined the structural logic at the cell surface, showing TCR and BTN3A1-IgV binding to BTN2A1-IgV are mutually exclusive and supporting a composite-ligand model.

   Evidence NMR, structural modeling, mutagenesis, and TCR activation assays on IgV domains

   PMID:36995939

   Open questions at the time

   • Cis IgV interaction shown non-essential, leaving its biological purpose open
   • Did not resolve the intracellular pAg-sensing step
5. 2023 High

   Localized pAg sensing to the intracellular domains, demonstrating HMBPP binds BTN3A1 (not BTN2A1) and that BTN2A1 B30.2 homodimerization is required to engage HMBPP-bound BTN3A1.

   Evidence Mutagenesis, size-exclusion chromatography, [31P]-NMR, ITC, and IFN-γ ELISA on internal-domain constructs

   PMID:37171180

   Open questions at the time

   • How intracellular B30.2 engagement is transmitted to ectodomain rearrangement not shown
   • Role of linker residues L318/L325 in full-length signaling untested
6. 2024 Medium

   Demonstrated BTN2A1 is a druggable target by showing agonist antibody engagement enhances γδ T cell killing and triggers tumor pyroptosis.

   Evidence Cytotoxicity, caspase 3/7, and holotomographic imaging assays with antibody 107G3B5 on tumor lines

   PMID:39302336

   Open questions at the time

   • Molecular basis of agonism not biochemically reconstituted
   • Pyroptotic pathway downstream of caspase activation not detailed
7. 2024 Medium

   Extended BTN2A1 function beyond γδ T cells, showing antibody engagement reprograms M2-like macrophages toward M1 via a defined SYK/ERK signaling cascade.

   Evidence Antibody treatment with SYK/ERK inhibitor experiments and ex vivo macrophage differentiation assays

   PMID:39325623

   Open questions at the time

   • Whether native ligands drive this signaling, or only the antibody, is unknown
   • Receptor proximal events linking BTN2A1 to SYK recruitment not defined
8. 2024 Medium

   Provided a full-length structural mechanism showing pAg bridges the intracellular B30.2 domains and TCR engagement drives ectodomain rearrangement into a 'pliers-like' grip.

   Evidence Cryo-EM of full-length BTN3A1-BTN3A2-BTN2A1 complexes with and without TCR (preprint)

   PMID:bio_10.1101_2024.10.02.616253

   Open questions at the time

   • Preprint, not peer-reviewed
   • Dynamics of the transition state between cis and TCR-bound states not captured
9. 2024 Low

   Linked BTN2A1 surface upregulation to oncogenic transformation and identified candidate regulators of its surface dynamics.

   Evidence Step-wise oncogenic mutagenesis in organoids with surface and interactome mapping (preprint)

   PMID:bio_10.1101_2024.11.19.624272

   Open questions at the time

   • Preprint; PHLDB2/SYNJ2/CARMIL1 interactions identified by interactome mapping without mechanistic validation
   • Causal link between specific oncogenic mutations and BTN2A1 induction not dissected
10. 2025 Medium

    Resolved which BTN3A1 B30.2 residues undergo pAg- and BTN2A1-induced conformational change, mapping the dynamic basis of binding.

    Evidence 19F solution NMR of BTN3A1 point mutants with binding affinity measurements

    PMID:40079188

    Open questions at the time

    • Single lab, no independent replication
    • Conformational changes in BTN2A1 itself not similarly mapped
11. 2025 Medium

    Showed BTN2A1 can be transferred between cells by trogocytosis, sensitizing recipient cells to γδ T cell lysis and expanding how BTN2A1 surface levels are regulated.

    Evidence BTN2A1-knockout cells, trogocytosis and cytotoxicity assays, flow cytometry

    PMID:41066236

    Open questions at the time

    • In vivo relevance of trogocytic transfer unproven
    • Whether transferred BTN2A1 retains intracellular pAg-sensing capacity unaddressed
12. 2026 Medium

    Demonstrated a pharmacological route to enhance γδ T cell sensitivity by showing metformin upregulates BTN2A1/BTN3A1 via AMPK.

    Evidence AMPK inhibitor experiments, surface expression and cytotoxicity assays, xenograft models in esophageal cancer

    PMID:42248853

    Open questions at the time

    • Mechanism linking AMPK to BTN transcription/surface trafficking not defined
    • Effect generality across tumor types not established

• How the intracellular pAg-induced B30.2 engagement is mechanically transmitted across the membrane to drive the ectodomain rearrangement that licenses BTN2A1–Vγ9 binding remains incompletely defined.
• No peer-reviewed full-length structure capturing the transition
• Surface trafficking regulators of BTN2A1 not mechanistically validated
• Physiological (non-antibody) triggers of BTN2A1 signaling in macrophages unknown